BioWorld

May 19, 2009

Oxford BioTherapeutics, GSK in $370M Cancer Drug Deal

Smallish UK biotech Oxford BioTherapeutics Ltd. stands to gain $370 million under a new partnership with drug giant GlaxoSmithKline plc to discover, develop and commercialize therapeutic antibodies aimed at treating primary, metastatic and recurring forms of cancer. (BioWorld Today) Read More

FDA-Stalled Bone Cancer Drug Lures Takeda: $66.7M for IDM

Biovail to Buy Cambridge Lab's Tetrabenazine for Potential $230M

Economic Woes Forcing Sector to Adopt New Business Models

Onyx Sues Partner Bayer over Nexavar Spinoff

Sciele Gets Pain Pipeline with $150M Victory Buy

Other News To Note

ECCMID Roundup

Clinic Roundup

ATS Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 29, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...